Ultragenyx Pharmaceutical Inc has a consensus price target of $100.4, established from looking at the 60 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, JP Morgan, and Cantor Fitzgerald on March 18, 2024, February 27, 2024, and February 27, 2024. With an average price target of $95.67 between JP Morgan, JP Morgan, and Cantor Fitzgerald, there's an implied 104.33% upside for Ultragenyx Pharmaceutical Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/18/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 96.5% | JP Morgan | Anupam Rama | $88 → $92 | Maintains | Overweight | Get Alert |
02/27/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 87.95% | JP Morgan | Cory Kasimov | $84 → $88 | Maintains | Overweight | Get Alert |
02/27/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 128.53% | Cantor Fitzgerald | Kristen Kluska | → $107 | Maintains | Overweight | Get Alert |
02/21/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 137.08% | Canaccord Genuity | Whitney Ijem | $110 → $111 | Maintains | Buy | Get Alert |
02/16/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 2.52% | Wedbush | Laura Chico | $47 → $48 | Maintains | Neutral | Get Alert |
02/15/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 143.49% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
01/30/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 45.24% | Baird | Joel Beatty | $57 → $68 | Maintains | Outperform | Get Alert |
01/19/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 143.49% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
12/08/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 53.78% | Wells Fargo | Tiago Fauth | → $72 | Initiates | → Overweight | Get Alert |
11/03/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 79.41% | Morgan Stanley | Jeffrey Hung | $90 → $84 | Maintains | Overweight | Get Alert |
10/25/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 177.66% | Piper Sandler | Christopher Raymond | $135 → $130 | Maintains | Overweight | Get Alert |
10/10/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 92.23% | Morgan Stanley | Jeffrey Hung | $95 → $90 | Maintains | Overweight | Get Alert |
09/25/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 143.49% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
08/04/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 102.9% | Morgan Stanley | Jeffrey Hung | $95 → $95 | Reiterates | Overweight → Overweight | Get Alert |
08/01/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 75.14% | HC Wainwright & Co. | Ed Arce | → $82 | Reiterates | Buy → Buy | Get Alert |
06/14/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 105.04% | Credit Suisse | Tiago Fauth | → $96 | Assumes | → Outperform | Get Alert |
06/07/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 184.07% | Citigroup | Yigal Nochomovitz | $130 → $133 | Maintains | Buy | Get Alert |
06/06/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 70.87% | Evercore ISI Group | Liisa Bayko | $60 → $80 | Upgrade | In-Line → Outperform | Get Alert |
06/06/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $46.82 | 8.93% | Wedbush | Laura Chico | $48 → $51 | Maintains | Neutral | Get Alert |
The latest price target for Ultragenyx Pharmaceutical (NASDAQ: RARE) was reported by JP Morgan on March 18, 2024. The analyst firm set a price target for $92.00 expecting RARE to rise to within 12 months (a possible 96.50% upside). 23 analyst firms have reported ratings in the last year.
The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ: RARE) was provided by JP Morgan, and Ultragenyx Pharmaceutical maintained their overweight rating.
The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2023 when Evercore ISI Group raised their price target to $80. Evercore ISI Group previously had an in-line for Ultragenyx Pharmaceutical Inc.
The last downgrade for Ultragenyx Pharmaceutical Inc happened on August 1, 2022 when Evercore ISI Group changed their price target from $95 to $60 for Ultragenyx Pharmaceutical Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a maintained with a price target of $88.00 to $92.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $46.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.